Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 336

1.

Inhibition of c-kit tyrosine kinase by imatinib mesylate induces apoptosis in mast cells in rheumatoid synovia: a potential approach to the treatment of arthritis.

Juurikivi A, Sandler C, Lindstedt KA, Kovanen PT, Juutilainen T, Leskinen MJ, Mäki T, Eklund KK.

Ann Rheum Dis. 2005 Aug;64(8):1126-31.

2.

Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis.

Noordenbos T, Yeremenko N, Gofita I, van de Sande M, Tak PP, Caňete JD, Baeten D.

Arthritis Rheum. 2012 Jan;64(1):99-109. doi: 10.1002/art.33396.

3.

Mast cell-derived tryptase inhibits apoptosis of human rheumatoid synovial fibroblasts via rho-mediated signaling.

Sawamukai N, Yukawa S, Saito K, Nakayamada S, Kambayashi T, Tanaka Y.

Arthritis Rheum. 2010 Apr;62(4):952-9. doi: 10.1002/art.27331.

4.

Expression of stem cell factor (SCF) and SCF receptor (c-kit) in synovial membrane in arthritis: correlation with synovial mast cell hyperplasia and inflammation.

Ceponis A, Konttinen YT, Takagi M, Xu JW, Sorsa T, Matucci-Cerinic M, Santavirta S, Bankl HC, Valent P.

J Rheumatol. 1998 Dec;25(12):2304-14.

PMID:
9858422
5.

Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit.

Verstovsek S, Akin C, Manshouri T, Quintás-Cardama A, Huynh L, Manley P, Tefferi A, Cortes J, Giles FJ, Kantarjian H.

Leuk Res. 2006 Nov;30(11):1365-70. Epub 2006 Jun 23.

PMID:
16797704
6.

Tumour necrosis factor alpha (TNF-alpha) interferes with Fas-mediated apoptotic cell death on rheumatoid arthritis (RA) synovial cells: a possible mechanism of rheumatoid synovial hyperplasia and a clinical benefit of anti-TNF-alpha therapy for RA.

Ohshima S, Mima T, Sasai M, Nishioka K, Shimizu M, Murata N, Yoshikawa H, Nakanishi K, Suemura M, McCloskey RV, Kishimoto T, Saeki Y.

Cytokine. 2000 Mar;12(3):281-8.

PMID:
10704256
7.

[Effect of tyrosine kinase inhibitor Imatinib mesylate on proliferation, differentiation and apoptosis of Kasumi-1 leukemia cell line].

Wang LH, Rao Q, Wang M, Wang JX.

Zhonghua Xue Ye Xue Za Zhi. 2005 Aug;26(8):449-52. Chinese.

PMID:
16383232
8.

EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation.

Pan J, Quintás-Cardama A, Kantarjian HM, Akin C, Manshouri T, Lamb P, Cortes JE, Tefferi A, Giles FJ, Verstovsek S.

Blood. 2007 Jan 1;109(1):315-22. Epub 2006 Aug 15.

9.

Selective activation of mast cells in rheumatoid synovial tissue results in production of TNF-alpha, IL-1beta and IL-1Ra.

Sandler C, Lindstedt KA, Joutsiniemi S, Lappalainen J, Juutilainen T, Kolah J, Kovanen PT, Eklund KK.

Inflamm Res. 2007 Jun;56(6):230-9.

PMID:
17607547
10.

Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation.

Hamaï A, Richon C, Meslin F, Faure F, Kauffmann A, Lecluse Y, Jalil A, Larue L, Avril MF, Chouaib S, Mehrpour M.

Oncogene. 2006 Dec 7;25(58):7618-34. Epub 2006 Sep 18. Erratum in: Oncogene. 2007 Feb 22;26(8):1256.

PMID:
16983347
11.

Imatinib mesylate (STI571) interference with growth of neuroectodermal tumour cell lines does not critically involve c-Kit inhibition.

Te Kronnie G, Timeus F, Rinaldi A, Crescenzio N, Spinelli M, Rosolen A, Ricotti E, Basso G.

Int J Mol Med. 2004 Sep;14(3):373-82.

PMID:
15289888
12.

Sensitivity of human cells bearing oncogenic mutant kit isoforms to the novel tyrosine kinase inhibitor INNO-406.

Pan J, Quintás-Cardama A, Manshouri T, Cortes J, Kantarjian H, Verstovsek S.

Cancer Sci. 2007 Aug;98(8):1223-5. Epub 2007 May 22.

13.

Stem cell factor and its receptor c-Kit as targets for inflammatory diseases.

Reber L, Da Silva CA, Frossard N.

Eur J Pharmacol. 2006 Mar 8;533(1-3):327-40. Epub 2006 Feb 17. Review.

PMID:
16483568
14.

Protease-activated receptor 2 mediates the proinflammatory effects of synovial mast cells.

Palmer HS, Kelso EB, Lockhart JC, Sommerhoff CP, Plevin R, Goh FG, Ferrell WR.

Arthritis Rheum. 2007 Nov;56(11):3532-40.

15.

Imatinib mesylate (STI571; Glivec)--a new approach in the treatment of biliary tract cancer?

Wiedmann M, Kreth F, Feisthammel J, Deininger M, Mössner J, Caca K.

Anticancer Drugs. 2003 Oct;14(9):751-60.

PMID:
14551510
16.

Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit.

Akin C, Brockow K, D'Ambrosio C, Kirshenbaum AS, Ma Y, Longley BJ, Metcalfe DD.

Exp Hematol. 2003 Aug;31(8):686-92.

PMID:
12901973
17.

Imatinib mesylate inhibits platelet derived growth factor stimulated proliferation of rheumatoid synovial fibroblasts.

Sandler C, Joutsiniemi S, Lindstedt KA, Juutilainen T, Kovanen PT, Eklund KK.

Biochem Biophys Res Commun. 2006 Aug 18;347(1):31-5. Epub 2006 Jun 21.

PMID:
16806061
18.

C-kit inhibition by imatinib mesylate attenuates progenitor cell expansion and inhibits liver tumor formation in mice.

Knight B, Tirnitz-Parker JE, Olynyk JK.

Gastroenterology. 2008 Sep;135(3):969-79, 979.e1. doi: 10.1053/j.gastro.2008.05.077. Epub 2008 Jun 3.

PMID:
18602920
19.

Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis.

Paniagua RT, Sharpe O, Ho PP, Chan SM, Chang A, Higgins JP, Tomooka BH, Thomas FM, Song JJ, Goodman SB, Lee DM, Genovese MC, Utz PJ, Steinman L, Robinson WH.

J Clin Invest. 2006 Oct;116(10):2633-42. Epub 2006 Sep 14.

20.

Macrophage migration inhibitory factor: a mediator of matrix metalloproteinase-2 production in rheumatoid arthritis.

Pakozdi A, Amin MA, Haas CS, Martinez RJ, Haines GK 3rd, Santos LL, Morand EF, David JR, Koch AE.

Arthritis Res Ther. 2006;8(4):R132.

Supplemental Content

Support Center